Related Experiment Videos
A silent killer--often preventable.
Laurie G Futterman1, Louis Lemberg
1Division of Cardiology, Department of Medicine, University of Miami School of Medicine, Miami, Fla, USA.
Summary
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious, preventable conditions affecting millions. Early screening and prophylactic therapy, like enoxaparin, are crucial for high-risk patients.
Area of Science:
- Medical research
- Cardiovascular health
- Thrombosis prevention
Background:
- Deep vein thrombosis (DVT) and its severe complication, pulmonary embolism (PE), cause over 250,000 U.S. hospitalizations annually.
- Venous thromboembolism (VTE) affects two million people yearly, with rising prevalence due to an aging population.
- Despite being preventable, there's a significant failure in screening, diagnosing, and initiating prophylactic therapy for at-risk patients.
Observation:
- The landmark MEDENOX study identified key VTE risk factors: prior VTE, acute infections, cancer, age >75, and chronic respiratory disease.
- Emergency department physicians and nurses, along with caregivers for bedridden patients, need heightened awareness of these risk factors.
- A critical gap exists in the proactive management of VTE, leading to preventable morbidity and mortality.
Findings:
- The MEDENOX study confirmed the effectiveness of low molecular weight heparin (LMWH), specifically enoxaparin, in preventing VTE.
- Risk stratification based on identified factors can guide prophylactic treatment decisions.
- Early intervention with anticoagulants like enoxaparin significantly reduces VTE incidence.
Implications:
- Implementing routine VTE risk assessments and prophylactic measures can decrease hospitalizations and mortality.
- Enhanced physician and nurse education on VTE risk factors is essential for improved patient outcomes.
- Widespread adoption of evidence-based prophylaxis, such as enoxaparin, can mitigate the growing burden of VTE.